Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.80 |
| ▸ | NPC1 | O15118 | 7/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | RAB9A | P51151 | 7/20 | 0.78 |
| ▸ | HTT | P42858 | 5/20 | 0.78 |
| ▸ | CASP3 | P42574 | 2/20 | 0.78 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.78 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.78 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.78 |
| ▸ | MMP2 | P08253 | 2/20 | 0.78 |
| ▸ | MMP9 | P14780 | 2/20 | 0.78 |
| ▸ | MMP8 | P22894 | 2/20 | 0.78 |
| ▸ | MMP13 | P45452 | 2/20 | 0.78 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.70 |
| ▸ | RELA | Q04206 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217725 | 0.92 | CHEK2 (0.87) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL3195153 | 0.90 | CHEK2 (0.65) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL20982761 | 0.89 | NPC1 (0.97) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL20982700 | 0.88 | NPC1 (0.94) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL5566191 | 0.88 | NPC1 (1.00) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL7040027 | 0.87 | CHEK2 (0.62) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL6643380 | 0.86 | CHEK2 (1.00) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL5219206 | 0.85 | NPBWR1 (0.77) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL31049578 | 0.85 | NPBWR1 (1.00) | NPBWR1NPC1MAPTRAB9AHTT | |
| SCHEMBL17898258 | 0.85 | NPBWR1 (1.00) | NPBWR1NPC1MAPTRAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3710442-A2 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | The Scripps Research Institute (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | NPBWR1 1710/4885NPC1 2928/4885MAPT 3701/4885 |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | NPBWR1 3449/4885NPC1 2591/4885MAPT 60/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | NPBWR1 3449/4885NPC1 2591/4885MAPT 60/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | NPBWR1 2730/4885NPC1 3036/4885MAPT 4067/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | NPBWR1 1710/4885NPC1 2928/4885MAPT 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.